Keyword

second-generation TKIs

Description: Second-generation TKIs are tyrosine kinase inhibitor drugs developed to treat cancers and other diseases, including chronic myeloid leukemia and EGFR-mutated lung cancer.
OpenAlex ID: keywords/second-generation-tkis
2014 · D. Ross Camidge, William Pao, et al. · Nature Reviews Clinical Oncology · 877
2007 · Jane F Apperley · The Lancet Oncology · 666
2020 · Theodore P. Braun, Christopher A. Eide, et al. · Cancer Cell · 507
2012 · N C P Cross, H E White, et al. · Leukemia · 391
2011 · Geoffrey R. Oxnard, Maria E. Arcila, et al. · Clinical Cancer Research · 363
2022 · Elias Jabbour, Hagop Kantarjian · American Journal of Hematology · 312
2024 · Elias Jabbour, Hagop Kantarjian · American Journal of Hematology · 259
2014 · Elias Jabbour, Hagop Kantarjian · American Journal of Hematology · 221
2023 · Jayastu Senapati, Koji Sasaki, et al. · Blood Cancer Journal · 209
2024 · Andreas Hochhaus, Jianxiang Wang, et al. · New England Journal of Medicine · 204
2016 · Elias Jabbour, Hagop Kantarjian · American Journal of Hematology · 194
2013 · Simona Soverini, Susan Branford, et al. · Leukemia Research · 193
2015 · Elias Jabbour, Hagop Kantarjian, et al. · Clinical Lymphoma Myeloma & Leukemia · 166
2014 · Kathrin M. Bernt, Stephen P. Hunger · Frontiers in Oncology · 160
2012 · Elias Jabbour, Hagop Kantarjian · American Journal of Hematology · 150
2018 · Niki Karachaliou, Manuel Fernandez-Bruno, et al. · Translational Cancer Research · 135
2009 · Alfonso Quintás-Cardama, Hagop Kantarjian, et al. · Nature Reviews Clinical Oncology · 127
2021 · Jorge Cortes, Fabian Lang · Journal of Hematology & Oncology · 126
Works count: 699
Citation count: 12,590
Year
Topic
Type